KR20170081253A - 항-il-1베타 항체 및 이의 사용 방법 - Google Patents

항-il-1베타 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20170081253A
KR20170081253A KR1020177015590A KR20177015590A KR20170081253A KR 20170081253 A KR20170081253 A KR 20170081253A KR 1020177015590 A KR1020177015590 A KR 1020177015590A KR 20177015590 A KR20177015590 A KR 20177015590A KR 20170081253 A KR20170081253 A KR 20170081253A
Authority
KR
South Korea
Prior art keywords
antibody
amino acid
human
beta
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177015590A
Other languages
English (en)
Korean (ko)
Inventor
스테판 뎅글
피터 미카엘 휠스만
크리스찬 가쓰너
세바스찬 브로이어
올라프 문디글
가이 조지스
랄프 슈마허
구이도 하르트만
사비네 그뤼너
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20170081253A publication Critical patent/KR20170081253A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177015590A 2014-11-10 2015-11-06 항-il-1베타 항체 및 이의 사용 방법 Withdrawn KR20170081253A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192523.0 2014-11-10
EP14192523 2014-11-10
PCT/EP2015/075875 WO2016075034A1 (en) 2014-11-10 2015-11-06 ANTI-IL-1beta ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
KR20170081253A true KR20170081253A (ko) 2017-07-11

Family

ID=51868114

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177015590A Withdrawn KR20170081253A (ko) 2014-11-10 2015-11-06 항-il-1베타 항체 및 이의 사용 방법

Country Status (15)

Country Link
US (1) US10344085B2 (enExample)
EP (1) EP3218402A1 (enExample)
JP (1) JP6787888B2 (enExample)
KR (1) KR20170081253A (enExample)
CN (1) CN107074942A (enExample)
AR (1) AR102594A1 (enExample)
AU (1) AU2015345320A1 (enExample)
BR (1) BR112017009817A2 (enExample)
CA (1) CA2963719A1 (enExample)
IL (1) IL251165A0 (enExample)
MX (1) MX2017005987A (enExample)
RU (1) RU2017120358A (enExample)
SG (1) SG11201702550WA (enExample)
TW (1) TW201632552A (enExample)
WO (1) WO2016075034A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210099053A (ko) * 2018-12-21 2021-08-11 에프. 호프만-라 로슈 아게 Vegf 및 il-1베타에 결합하는 항체 및 이의 사용 방법

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2417156T1 (sl) 2009-04-07 2015-06-30 Roche Glycart Ag Trivalentna, bispecifiäśna protitelesa
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重特異性抗体及び眼科に使用する方法
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
CN107074942A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 抗‑IL‑1β抗体和使用方法
JP2017534644A (ja) 2014-11-10 2017-11-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗ang2抗体及び使用方法
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
AR111761A1 (es) * 2017-05-16 2019-08-14 Cj Healthcare Corp Un método para purificar un anticuerpo o un fragmento de anticuerpo de este usando cromatografía de afinidad
WO2018212556A1 (en) * 2017-05-16 2018-11-22 Cj Healthcare Corporation A method for purifying an antibody or an antibody fragment thereof using affinity chromatography
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
IL318916A (en) * 2018-01-26 2025-04-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN117024587A (zh) * 2019-03-07 2023-11-10 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
CA3143039A1 (en) * 2019-06-11 2020-12-17 Bioatla, Inc. Conditionally active anti-epcam antibodies, antibody fragments, their immunoconjugates and uses thereof
CN114524875B (zh) * 2021-11-11 2023-07-25 江苏莱森生物科技研究院有限公司 偶联IL-1β单克隆抗体的纳米硅球及应用
CN117126278B (zh) * 2023-10-26 2024-01-05 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
EP1481010A2 (en) * 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1 beta analogs
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
CA2509136C (en) * 2003-01-24 2013-10-29 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
US20050282233A1 (en) 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
BRPI1007371A2 (pt) * 2009-01-29 2018-03-27 Abbott Lab proteínas de ligação a il-1
UY32949A (es) * 2009-10-15 2011-02-28 Abbott Lab Proteínas de unión a il-1
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
JP2013537539A (ja) * 2010-08-13 2013-10-03 ジェネンテック, インコーポレイテッド 疾患の治療のためのIL−1β及びIL−18に対する抗体
NZ607510A (en) * 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
KR20130133247A (ko) * 2010-12-21 2013-12-06 애브비 인코포레이티드 Il-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
AU2012275346B2 (en) 2011-06-29 2016-03-17 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
KR20150023957A (ko) 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
EA201500370A1 (ru) 2012-09-28 2015-08-31 Бёрингер Ингельхайм Интернациональ Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
EP2900260A1 (en) 2012-09-28 2015-08-05 Boehringer Ingelheim International GmbH Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
EA034963B1 (ru) 2012-11-08 2020-04-13 Клиасайд Байомедикал, Инк. Способ лечения расстройства заднего сегмента глаза
BR112015010722A2 (pt) 2012-11-09 2017-08-22 Pfizer Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CA2904448A1 (en) * 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
JP2016528167A (ja) * 2013-04-29 2016-09-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ヒトFcRn結合改変抗体及び使用方法
CA2923591A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Combination therapy with an anti-ang2 antibody and a cd40 agonist
EP3835318B1 (en) 2014-01-15 2025-10-29 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
JP2017534644A (ja) 2014-11-10 2017-11-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗ang2抗体及び使用方法
CN107074942A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 抗‑IL‑1β抗体和使用方法
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重特異性抗体及び眼科に使用する方法
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
CN110691790A (zh) 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210099053A (ko) * 2018-12-21 2021-08-11 에프. 호프만-라 로슈 아게 Vegf 및 il-1베타에 결합하는 항체 및 이의 사용 방법

Also Published As

Publication number Publication date
JP2017534646A (ja) 2017-11-24
CN107074942A (zh) 2017-08-18
MX2017005987A (es) 2017-06-29
US20170247447A1 (en) 2017-08-31
BR112017009817A2 (pt) 2018-02-14
SG11201702550WA (en) 2017-04-27
AR102594A1 (es) 2017-03-08
JP6787888B2 (ja) 2020-11-18
TW201632552A (zh) 2016-09-16
US10344085B2 (en) 2019-07-09
IL251165A0 (en) 2017-04-30
AU2015345320A1 (en) 2017-04-06
EP3218402A1 (en) 2017-09-20
CA2963719A1 (en) 2016-05-19
RU2017120358A (ru) 2018-12-13
RU2017120358A3 (enExample) 2019-05-29
WO2016075034A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
US10730938B2 (en) Bispecific antibodies and methods of use in ophthalmology
US10344085B2 (en) Anti-IL-1beta antibodies
AU2016333511B2 (en) Humanized anti-human CD19 antibodies and methods of use
US10087246B2 (en) Anti-PDGF-B antibodies and methods of use
KR20150030755A (ko) 항-바이오틴 항체 및 사용 방법
KR20150023938A (ko) 항-테오필린 항체 및 이의 사용 방법
US11820816B2 (en) Anti-VEGF antibodies and methods of use
HK1238257A1 (en) Anti-il-1beta antibodies and methods of use
HK1236207A1 (en) Bispecific antibodies and methods of use in ophthalmology

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170608

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination